Abbott Stock Insiders


USD 111.48  0.55  0.49%   

Abbott Laboratories employes about 113 K people. The company is managed by 58 executives with total tenure of roughly 388 years, averaging almost 6.0 years of service per executive having 1948.28 employees per reported executive. Break down Abbott Laboratories management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Abbott Laboratories future performance.
Please continue to Trending Equities.
  Robert Ford  CEO
President, Chief Executive Officer, Chief Operating Officer, Director
  Miles White  Chairman
Chairman, CEO and Chairman of Executive Committee
  Roger Bird  President
Senior Vice President - U.S. Nutrition

Abbott Laboratories Return on Sales


Abbott Laboratories Management Team Effectiveness

Abbott Laboratories has Return on Asset of 8.56 % which means that on every $100 spent on asset, it made $8.56 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 22.26 %, implying that it generated $22.26 on every 100 dollars invested. Abbott Laboratories management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to 14.55 in 2022. Return on Average Assets is likely to drop to 0.08 in 2022. Abbott Laboratories Total Liabilities is comparatively stable at the moment as compared to the past year. Abbott Laboratories reported Total Liabilities of 39.17 Billion in 2021. Liabilities Non Current is likely to gain to about 26.6 B in 2022, whereas Current Liabilities is likely to drop slightly above 11.4 B in 2022.

Abbott Laboratories Quarterly Total Assets

74.2 Billion

Abbott Laboratories Weighted Average Shares is comparatively stable at the moment as compared to the past year. Abbott Laboratories reported Weighted Average Shares of 1.77 Billion in 2021. Weighted Average Shares Diluted is likely to gain to about 1.9 B in 2022, whereas Issuance Purchase of Equity Shares is likely to drop (2.1 B) in 2022.

Abbott Laboratories Workforce Comparison

Abbott Laboratories is number one stock in number of employees category among related companies. The total workforce of Medical Devices industry is presently estimated at about 1.59 Million. Abbott Laboratories holds roughly 113,000 in number of employees claiming about 7% of all equities under Medical Devices industry.

Abbott Laboratories Profit Margins

The company has Net Profit Margin of 18.78 %, which may imply that it executes well on its competitive polices and has reasonable control over its expenses and variable costs. This is very large. In the same way, it shows Net Operating Margin of 22.96 %, which entails that for every 100 dollars of revenue, it generated 0.23 of operating income.

Abbott Laboratories Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abbott Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abbott Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Abbott Laboratories insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Abbott Laboratories Benchmark Summation

Abbott Laboratories Notable Stakeholders

An Abbott Laboratories stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Abbott Laboratories often face trade-offs trying to please all of them. Abbott Laboratories' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Abbott Laboratories' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Robert Ford - President, Chief Executive Officer, Chief Operating Officer, DirectorProfile
Miles White - Chairman, CEO and Chairman of Executive CommitteeProfile
Roger Bird - Senior Vice President - U.S. NutritionProfile
Heather Mason - Senior Vice President - Abbott Diabetes CareProfile
JeanYves Pavee - Senior Vice President - Established Pharmaceuticals, Developed MarketsProfile
Stephen Fussell - Executive Vice President - Human ResourcesProfile
Thomas Frinzi - Senior Vice President - Abbott Medical OpticsProfile
Murthy Simhambhatla - Senior Vice President - Abbott Medical OpticsProfile
Michael Rousseau - President - Cardiovascular and NeuromodulationProfile
Hubert Allen - Executive Vice President, General Counsel, SecretaryProfile
Charles Foltz - Senior Vice President - Abbott VascularProfile
Brian Yoor - Chief Financial Officer, Executive Vice President - FinanceProfile
Jared Watkin - Senior Vice President - Diabetes CareProfile
Scott White - Senior Vice President - International NutritionProfile
Deepak Nath - Senior Vice President - Abbott VascularProfile
Jaime Contreras - Senior Vice President - Core Laboratory Diagnostics, Commercial OperationsProfile
Andrew Lane - Senior Vice President - Established Pharmaceuticals, Emerging MarketsProfile
Georges Vos - Senior Vice President - Established Pharmaceuticals, Emerging MarketsProfile
Eric Fain - Senior Vice President Group President - Cardiovascular and NeuromodulationProfile
John Capek - Executive Vice President - VenturesProfile
Joseph Manning - Senior Vice President - Abbott Nutrition InternationalProfile
Michael Warmuth - Executive Vice President - Established PharmaceuticalsProfile
Robert Funck - Chief Financial Officer, Executive Vice President - FinanceProfile
Daniel Salvadori - Senior Vice President - Established Pharmaceuticals, Latin America.Profile
Richard Ashley - Executive VP of Corporate Devel.Profile
Brian Blaser - Executive VP of Diagnostic ProductsProfile
Thomas Freyman - Executive VP of Fin. and Admin.Profile
Samuel Scott - Independent DirectorProfile
James Farrell - Independent DirectorProfile
Phebe Novakovic - Independent DirectorProfile
Roxanne Austin - Independent DirectorProfile
Sally Blount - Independent DirectorProfile
Daniel Starks - Independent DirectorProfile
Robert Alpern - Independent DirectorProfile
Glenn Tilton - Independent DirectorProfile
Darren McDew - Independent DirectorProfile
Patricia Gonzalez - Independent DirectorProfile
Nancy McKinstry - Independent DirectorProfile
Michelle Kumbier - Independent DirectorProfile
Edward Liddy - Independent DirectorProfile
John Stratton - Independent DirectorProfile
William Osborn - Lead Independent DirectorProfile
Christopher Scoggins - Senior Vice President - Rapid DiagnosticsProfile
Michael Dale - Senior Vice President - Structural HeartProfile
Sammy Karam - Senior Vice President - Established Pharmaceuticals, Emerging MarketsProfile
Michael Pederson - Senior Vice President - Electrophysiology and Heart FailureProfile
Lisa Earnhardt - Executive Vice President - Medical DevicesProfile
Alejandro Wellisch - Senior Vice President - Established Pharmaceuticals, Latin AmericaProfile
Christopher Calamari - Senior Vice President - U.S. NutritionProfile
Charles Brynelsen - Senior Vice President - Abbott VascularProfile
Gregory Ahlberg - Senior Vice President - Core Laboratory Diagnostics, Commercial OperationsProfile
Philip Boudreau - Vice President - Finance, ControllerProfile
John Ginascol - Executive Vice President - Core DiagnosticsProfile
Michael Roman - Independent DirectorProfile
Mary Moreland - Executive Vice President of Human ResourcesProfile
Randel Woodgrift - Senior Vice President - CRMProfile
Louis Morrone - Senior Vice President - Rapid DiagnosticsProfile
Andrea Wainer - Executive Vice President - Rapid and Molecular DiagnosticsProfile

About Abbott Laboratories Management Performance

The success or failure of an entity such as Abbott Laboratories often depends on how effective the management is. Abbott Laboratories management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Abbott management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Abbott management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Return on Investment 15.99  14.55 
Return on Average Assets 0.1  0.08 
Return on Average Equity 0.20  0.16 
Return on Invested Capital 0.26  0.21 
Return on Sales 0.20  0.18 
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois. Abbott Laboratories operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 113000 people.
The data published in Abbott Laboratories' official financial statements usually reflect Abbott Laboratories' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Abbott Laboratories. For example, before you start analyzing numbers published by Abbott accountants, it's critical to develop an understanding of what Abbott Laboratories' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Abbott Laboratories' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Abbott Laboratories' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Abbott Laboratories' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Abbott Laboratories. Please utilize our Beneish M Score to check the likelihood of Abbott Laboratories' management to manipulate its earnings.

Abbott Laboratories Workforce Analysis

Traditionally, organizations such as Abbott Laboratories use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Abbott Laboratories within its industry.

Abbott Laboratories Manpower Efficiency

Return on Abbott Laboratories Manpower

Revenue Per Employee391.5 K
Revenue Per Executive785.3 M
Net Income Per Employee56.1 K
Net Income Per Executive147.1 M
Working Capital Per Employee44 K
Working Capital Per Executive85.7 M
Today, most investors in Abbott Laboratories Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Abbott Laboratories' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Abbott Laboratories per employee as a starting point in their analysis.

Per Employee

Abbott Laboratories Per Employee Growth Over Time

Net Income Per Employee


Abbott Laboratories Net Income Per Employee is comparatively stable at the moment as compared to the past year. Abbott Laboratories reported Net Income Per Employee of 62,575 in 2021

Revenue Per Employee


Abbott Laboratories Revenue Per Employee is comparatively stable at the moment as compared to the past year. Abbott Laboratories reported Revenue Per Employee of 381,195 in 2021
Please continue to Trending Equities. Note that the Abbott Laboratories information on this page should be used as a complementary analysis to other Abbott Laboratories' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Abbott Stock analysis

When running Abbott Laboratories price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Is Abbott Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abbott Laboratories. If investors know Abbott will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abbott Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
Market Capitalization
196 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Abbott Laboratories is measured differently than its book value, which is the value of Abbott that is recorded on the company's balance sheet. Investors also form their own opinion of Abbott Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Abbott Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abbott Laboratories' market value can be influenced by many factors that don't directly affect Abbott Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abbott Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine Abbott Laboratories value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abbott Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.